185 related articles for article (PubMed ID: 18473971)
21. Nelarabine.
Gandhi V; Keating MJ; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2006 Jan; 5(1):17-8. PubMed ID: 16485343
[No Abstract] [Full Text] [Related]
22. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
Kisor DF
Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
[TBL] [Abstract][Full Text] [Related]
23. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
[TBL] [Abstract][Full Text] [Related]
24. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
25. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
[No Abstract] [Full Text] [Related]
26. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
28. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
29. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
[TBL] [Abstract][Full Text] [Related]
30. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Lech-Maranda E; Korycka A; Robak T
Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
[TBL] [Abstract][Full Text] [Related]
31. Nelarabine use in leukemias.
Kisor DF
Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400
[TBL] [Abstract][Full Text] [Related]
32. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Choi J; Foss F
Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
[TBL] [Abstract][Full Text] [Related]
34. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine.
Hebert ME; Greenberg ML; Chaffee S; Gravatt L; Hershfield MS; Elion GB; Kurtzberg J
Transplantation; 1991 Oct; 52(4):634-40. PubMed ID: 1926342
[TBL] [Abstract][Full Text] [Related]
36. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
37. Clofarabine in pediatric acute leukemia: current findings and issues.
Hijiya N; Barry E; Arceci RJ
Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
[TBL] [Abstract][Full Text] [Related]
40. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
